Live On CNBC, Ginkgo Bioworks CEO Jason Kelly Discusses AI & Drug Development; Comments On Biosecurity Deals
Portfolio Pulse from Happy Mohamed
Ginkgo Bioworks CEO, Jason Kelly, appeared on CNBC to discuss the role of artificial intelligence in drug development. No specific details about the company's performance or future plans were disclosed.
September 01, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ginkgo Bioworks CEO discussed AI in drug development on CNBC. No direct impact on DNA as no specific details were disclosed.
While the CEO of Ginkgo Bioworks discussed the role of AI in drug development, no specific details or plans that could directly impact DNA were disclosed. Therefore, the short-term impact on DNA's stock price is neutral.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50